FCGY yields 2000000.00% · ABBV yields 3.06%● Live data
📍 FCGY pulled ahead of the other in Year 1
Combined, FCGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FCGY + ABBV for your $10,000?
Forecastagility Corporation provides legacy application migration solutions to corporate clients in the United States and internationally. The company develops toolsets that migrate RPG and COBOL applications written for the IBM i-AS/400 environment to open platforms, such as Windows, Linux, or UNIX; and toolsets and services to modernize green screen applications for AS/400 and Mainframe environments. Its products include BABYi, a standard edition developer toolset and application server environment to migrate AS/400 RPG and COBOL applications to Windows; and BABY36 developer toolset, a suite of compilers, utilities, and operating system services that allow applications to be rehosted at the source code level, and recompiled and executed on the target platform. The company's products also comprise Infinite i, a suite of compilers, utilities, and operating system services that allow applications and programs to be migrated at the source code level, recompiled, and executed on the target platform; Infinite36 that migrates IBM System/36 RPG and COBOL applications to Windows, Linux, or UNIX; Infinite Cloud that create graphical screens from IBM i/AS400 green screens; and Infinite I Database Migration Tool for DB2 for IBM I (DB2/400) that enables to migrate IBM I, iSeries, and AS/400 data to Oracle or MS SQL environment. In addition, it offers migration and GUI creation services. The company was formerly known as Infinite Software Corporation and changed its name to Forecastagility Corporation in June 2019. Forecastagility Corporation was founded in 1975 and is based in Irvine, California.
Full FCGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.